Dose-ranging study
Dose-ranging study is a type of clinical trial where different doses of an investigational drug are tested to establish the dose which is both safe and effective. The main goal of a dose-ranging study is to determine the dose-response relationship of a new drug.
Overview[edit | edit source]
In a dose-ranging study, multiple doses of a drug are tested in parallel to evaluate the pharmacological effect at different dose levels. This type of study is typically performed in the early phases of clinical development after initial safety of the drug has been established through Phase I trials. The results of dose-ranging studies are used to establish the optimal dose for subsequent Phase III trials.
Design[edit | edit source]
The design of a dose-ranging study can vary depending on the drug and disease in question. However, most dose-ranging studies are randomized, double-blind, and placebo-controlled. Participants are randomly assigned to different dose groups, including a placebo group. The investigators and participants are blinded to the treatment assignments.
Outcome Measures[edit | edit source]
The primary outcome measure in a dose-ranging study is usually a biomarker or clinical endpoint that can be measured in a relatively short time. The choice of outcome measure depends on the drug and disease in question. The dose-response relationship is then established based on the observed changes in the outcome measure across the different dose groups.
Limitations[edit | edit source]
One of the main limitations of dose-ranging studies is that they are usually conducted in a relatively small number of participants and over a short period of time. Therefore, they may not detect all possible side effects of a drug, especially those that occur infrequently or over a long period of time. Furthermore, the dose-response relationship established in a dose-ranging study may not necessarily predict the long-term effectiveness or safety of the drug.
See Also[edit | edit source]
- Clinical trial
- Phase I clinical trial
- Phase III clinical trial
- Randomized controlled trial
- Double-blind study
- Placebo
| Dose-ranging study Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
